Search

Zentalis Pharmaceuticals Inc

Slēgts

3.53 -14.53

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.5

Max

3.61

Galvenie mērījumi

By Trading Economics

Ienākumi

-42M

-78M

EPS

-0.59

Darbinieki

106

EBITDA

-42M

-77M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+148.03% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-34M

297M

Iepriekšējā atvēršanas cena

18.06

Iepriekšējā slēgšanas cena

3.53

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. aug. 23:51 UTC

U.S. Industrial Production MoM data set for August 18, 2026, amid mixed economic signals and a forecasted increase of only 0.3%.

2026. g. 15. aug. 23:51 UTC

Bitcoin is trading roughly flat during Saturday's session, remaining near the lower end of its one-month trading range and below its 20-day moving average.

2026. g. 15. aug. 23:41 UTC

U.S. equities pull back amid disappointing retail sales and consumer sentiment, while geopolitical tensions and upcoming FOMC Minutes raise concerns for market stability.

2026. g. 15. aug. 23:41 UTC

European equity and bond markets closed for holiday as U.S. consumer sentiment drops, raising concerns over economic stability ahead of key data releases.

2026. g. 15. aug. 23:41 UTC

French, Italian, and Spanish markets closed for holiday as U.S. consumer sentiment drops sharply, raising concerns over inflation and potential Federal Reserve rate hikes.

2026. g. 15. aug. 23:41 UTC

Market Complacency Amidst Bond Volatility: U.S. Stocks Slip as Consumer Sentiment Falls and Retail Sales Decline, While Crypto Shows Resilience.

2026. g. 15. aug. 23:41 UTC

Cautious Optimism for Stabilization in Canadian Housing Prices Ahead of August 20 Index Release Amid Mixed Economic Signals.

2026. g. 15. aug. 23:41 UTC

Market Analysts Brace for Philadelphia Fed Manufacturing Index Release Amid Disappointing Retail Sales and Economic Uncertainty.

2026. g. 15. aug. 23:31 UTC

China's House Price Index YoY release on August 17, 2026, shows cautious optimism as home price declines ease amid mixed economic sentiment and global investor confidence.

2026. g. 15. aug. 23:11 UTC

Cautious Market Sentiment Ahead of July 2026 Building Permits Data Release, Forecasting 1.37 Million Issued Amid Recent Volatility

2026. g. 15. aug. 23:11 UTC

Australia's Westpac Consumer Confidence Index set for release amid cautious market sentiment and global economic uncertainties.

2026. g. 15. aug. 23:01 UTC

Upcoming Housing Starts Data Release on August 18, 2026, Amid Concerns Over Consumer Spending and Inflation Impacting Real Estate Markets.

2026. g. 15. aug. 23:01 UTC

U.S. Import Prices Expected to Rise 0.1% Amid Positive Inflation Sentiment and Reduced Fed Rate Hike Expectations

2026. g. 15. aug. 23:01 UTC

U.S. Export Prices Expected to Drop 0.2% Amid Slowing Inflation and Weak Retail Sales, Influencing Fed's Interest Rate Decisions

2026. g. 15. aug. 23:01 UTC

Market Awaits U.S. Building Permits Data Amid Optimism for Construction Growth and Infrastructure Investments.

2026. g. 15. aug. 23:01 UTC

U.S. Housing Starts Data for July 2026 Set to Release on August 18, Amid Mixed Market Sentiment and Forecast of 1.35 Million Units

2026. g. 15. aug. 23:01 UTC

EUR/CAD is trading roughly flat during after-market hours, showing little change since Friday's close and remaining near the lower end of its one-month range.

2026. g. 15. aug. 22:51 UTC

Australia's Westpac Consumer Confidence Index set for August 18, 2026 release amid global economic uncertainties and mixed market performance.

2026. g. 15. aug. 22:51 UTC

Canada's July 2026 Housing Starts Data Release Expected at 248K Amid Cautious Market Sentiment and Volatile Trends.

2026. g. 15. aug. 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% YoY Amid Global Economic Pressures and Potential BoJ Interest Rate Hike

2026. g. 15. aug. 22:51 UTC

Japan's July Exports YoY Data Set for Release Amid Optimistic Market Sentiment and Strong Nikkei Performance.

2026. g. 15. aug. 22:51 UTC

Japan's July trade balance expected to show a -680 billion yen deficit amid rising import costs and weak yen, while equities gain on Wall Street optimism.

2026. g. 15. aug. 22:51 UTC

Japan's Inflation Rate Release on August 20 Expected to Impact Monetary Policy and Market Sentiment Amid Anticipated Interest Rate Hikes.

2026. g. 15. aug. 22:41 UTC

NY Empire State Manufacturing Index Set for Release Amid Caution Over Disappointing Retail Sales and Economic Sentiment.

2026. g. 15. aug. 22:41 UTC

Canada's Inflation Rate Expected to Rise 0.5% in July Amid Mixed Market Sentiments and External Economic Pressures

2026. g. 15. aug. 22:41 UTC

MBA 30-Year Mortgage Rate Release on August 19 Expected to Impact Housing Market Amid Cooling Inflation and Interest Rates

2026. g. 15. aug. 22:41 UTC

Canada's July Inflation Rate Expected to Rise from 2.8% to 3%, Amid Geopolitical Tensions and Supply Chain Disruptions

2026. g. 15. aug. 22:41 UTC

Canada's Core Inflation Rate Release on August 17, 2026, Sparks Caution Among Investors Amid Geopolitical Tensions and Trade Uncertainty.

2026. g. 15. aug. 22:41 UTC

Avalanche is trading lower today, with no specific news identified. The asset remains within its one-month range amid shifting investment patterns among younger investors.

2026. g. 15. aug. 22:32 UTC

Japan's Machinery Orders MoM data set for August 18, 2026, with a forecasted increase of 0.079%, amid positive stock market sentiment and investor confidence in capital spending.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

148.03% augšup

Prognoze 12 mēnešiem

Vidējais 8.83 USD  148.03%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

5

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat